Trial Profile
A Phase Ib/II, Multicentre, Open Label, Randomized Study of BI 836845 in Combination With Enzalutamide, Versus Enzalutamide Alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following Disease Progression on Docetaxel-Based Chemotherapy and Abiraterone
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Aug 2023
Price :
$35
*
At a glance
- Drugs Xentuzumab (Primary) ; Enzalutamide
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 03 Aug 2023 Results of sub group analysis (n=96) evaluating the insulin-like growth factor (IGF) 1/2 neutralising antibody xentuzumab plus enzalutamide in metastatic castrate-resistant prostate cancer published in the British Journal of Cancer
- 26 Jul 2023 Status changed from active, no longer recruiting to completed.
- 06 Jul 2022 Planned End Date changed from 11 Aug 2022 to 12 Jul 2023.